STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions
Shots:
- STADA launched Hukyndra a citrate-free, high-concentration (100 mg/mL) biosimilar to adalimumab across immunology, oncology & ophthalmology to patients & caregivers in selected EU countries incl. France, Germany, Finland & Sweden while in further EU countries in coming mos.
- The Humira biosimilar consist 40mg/0.4 mL custom-designed pre-filled auto-injector pens, 40mg/0.4 mL & 80mg/0.8 mL pre-filled syringe presentations with 100mg/mL adalimumab. STADA supports Hukyndra's launch in national markets with educational materials & patient care programs
- Adalimumab marks 1st biosimilar developed in collaboration with Alvotech. Hukyndra biosimilar received approval in the EU & was valid in the 27 EU member countries, Norway, Iceland & Liechtenstein
Ref: Businesswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
